The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
The firm said the one-for-five reverse split will help address a looming delisting from the Nasdaq Capital Market by boosting the bid price per share above $1.00.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
NEW YORK (GenomeWeb News) – The University Medical Center at Johannes Gutenberg University Mainz in Germany (JGU) announced today separate deals to build out its capabilities in neuroscience research.
NEW YORK (GenomeWeb News) – Seahorse Biosciences said recently that it has licensed a patent from the Pioneer Valley Life Sciences Institute covering a method of analyzing the inner mechanics of a cell and how it makes and uses energy.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – EMD Millipore today announced that it has signed an agreement to acquire Seattle-based Amnis, a developer and manufacturer of high-speed cellular imaging instruments.
